HealthTree Logo
search more_vert
close
person Sign In / Create Account
Isatuximab Extends Survival When Used with Carfilzomib and Dexamethasone in Multiple Myeloma
Posted: May 19, 2020
Isatuximab Extends Survival When Used with Carfilzomib and Dexamethasone in Multiple Myeloma image

Adding isatuximab to a combination with carfilzomib and dexamethasone significantly extended remission and survival for relapsed myeloma patients, according to results from the Phase III IKEMA trial. 

The trial included 302 patients with relapsed myeloma from 69 centers in 16 countries. All study participants had 1-3 prior myeloma therapies. One group received IV isatuximab (Sarclisa) once weekly for four weeks, then overy other week in combination with twice weekly carfilzomib and dexamethasone. 

The other group received twice weekly carfilzomib and dexamethasone alone. The study was to determine overall response, the level of response, MRD status, and overall survival and safety. More data is anticipated as part of upcoming medical meetings. 

Sarclisa is a monoclonal antibody targeting CD38 and is now FDA approved to be used with pomalidomide and dexamethasone. Additional approvals are anticipated and we are happy to have yet another approved drug for use by myeloma patients. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube